This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Barrette Outdoor Living v. Fortress Iron (Fed. Cir., October 17, 2025) 2024-1231
Condensed IP
10 minutes
2 weeks ago
Barrette Outdoor Living v. Fortress Iron (Fed. Cir., October 17, 2025) 2024-1231
This episode focuses on an opinion by the United States Court of Appeals for the Federal Circuit, concerning a patent infringement case between Barrette Outdoor Living, Inc. (Plaintiff-Appellant) and Fortress Iron, LP, et al. (Defendants-Cross-Appellants). Barrette appealed a lower court's finding of non-infringement related to four of its patents, while Fortress cross-appealed the finding that the claims were not indefinite. The central issue on appeal revolved around the construction of ter...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
